Este articulo es un Preprint
Los preprints son informes de investigación preliminares que no han sido certificados por revisión por pares. No deben considerarse para guiar la práctica clínica o los comportamientos relacionados con la salud y no deben publicarse en los medios como información establecida.
Los preprints publicados en línea permiten a los autores recibir comentarios rápidamente, y toda la comunidad científica puede evaluar de forma independiente el trabajo y responder adecuadamente. Estos comentarios se publican junto con los preprints para que cualquiera pueda leer y servir como una revisión pospublicación.
Intravenous High-dose Anakinra Drops Venous Thrombosis and Myocardial Infarction in Severe and Critical COVID-19 Patients: A Propensity Score Matched Study (preprint)
researchsquare; 2024.
Preprint
en Inglés
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-3994466.v1
ABSTRACT
Introduction:
In our study, we aimed to evaluate the effect of high-dose intravenous anakinra treatment on the development of thrombotic events in severe and critical COVID-19 patients. Material andmethods:
This retrospective observational study was conducted at a tertiary referral center in Aksaray, Turkey. The study population consisted of two groups as follows; the patients receiving high-dose intravenous anakinra (anakinra group) added to background therapy and the patients treated with standard of care (SoC) as a historical control group. Age, gender, mcHIS scores, and comorbidities such as DM, HT, and CHD of the patients were determined as the variables to be matched.Results:
We included 114 patients in SoC and 139 patients in the Anakinra group in the study. Development of any thromboembolic event (5% vs 12.3%, p = 0.038; OR4.3) and PTE (2.9% vs 9.6%, p = 0.023; OR5.1) were lower in the Anakinra group than SoC. No patient experienced CVA and/or clinically evident DVT both in two arms. After 11 PS matching, 88 patients in SoC and 88 patients in the Anakinra group were matched and included in the analysis. In survival analysis, the development of any thromboembolic event, PTE, and MI were higher in SoC compared to Anakinra. Survival rate was also lower in patients with SoC arm than Anakinra in patients who had any thromboembolic event as well as MI.Conclusion:
In our study, the development of thrombosis was associated with hyperinflammation in patients with severe and critical COVID-19. Intravenous high-dose anakinra treatment decreases both venous and arterial events in patients with COVID-19.
Texto completo:
Disponible
Colección:
Preprints
Base de datos:
PREPRINT-RESEARCHSQUARE
Asunto principal:
Tromboembolia
/
Trombosis
/
Trombosis de la Vena
/
COVID-19
/
Infarto del Miocardio
/
Distrofia Miotónica
Idioma:
Inglés
Año:
2024
Tipo del documento:
Preprint
Similares
MEDLINE
...
LILACS
LIS